Through the partnership, she plans to share her experience—from consultation through recovery—across her social media platforms
The goal is to better support drug developers as programs move from laboratory research into clinical trials
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
New Yamuna Vihar facility to train 40 students annually through diploma-led, hands-on renal care education
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
Highlights Mirvetuximab-based regimen promise
Subscribe To Our Newsletter & Stay Updated
